Spur Therapeutics’ Post

Exciting announcement: Freeline is now Spur Therapeutics! Our new name and branding reflects our dedication to advancing the practice of genetic medicine, moving toward a new generation of therapies that can change the course of disease progression—and change the course of people’s lives. Check out our new website to learn more: www.spurtherapeutics.com Read the press release: https://lnkd.in/gGZJpQrN

Our CEO Michael Parini sat down with BiotechTV at our UK headquarters for an insightful discussion about our recent rebrand, our approach to developing transformational gene therapies for more diseases, and our mission to redefine what gene therapy can do for patients living with debilitating chronic conditions.

Imagine a world where the progression of debilitating chronic conditions can be stopped—with a single dose of genetic medicine. Where gene therapy can truly alter the course of a disease, and change the course of people’s lives.     It's that vision that spurs us forward, and has inspired our new name: Spur Therapeutics.     Learn more about our company, our pipeline, and how we’re advancing genetic medicine—toward more. Visit spurtherapeutics.com.

Today, we announced that we have completed enrollment in the Phase 1/2 GALILEO-1 clinical trial of FLT201, our #genetherapy candidate for #GaucherDisease.     Based on compelling data observed to date, a Phase 3 trial is expected to begin in 2025. https://lnkd.in/g8FtWkGV

Today, we announced positive new data from our #GBA1 #Parkinson’s disease research program. These data were presented at the inaugural GBA1 Meeting in Montreal. There is a rapidly emerging understanding of the role GBA1 mutations play in neurodegenerative diseases and much to learn. We were thrilled to be part of the inaugural meeting and share its aim to advance the understanding and treatment of GBA1 PD. https://lnkd.in/gsfuDKff

From the US to the UK, we marked #PrideMonth2024 with in-person gatherings, including lunch from one of our neighborhood LGBTQ-owned restaurants, virtual games, and thoughtful discussions. This month and every month, we embrace and celebrate all the ways, big and small, that we can work toward a more inclusive world. 🏳️🌈   #towardmore 

Our CEO Michael Parini had a chance to catch up with The BioHub Podcast for an engaging discussion on the progress and evolution of our company, the thinking behind our recent rebranding, and our vision for the future of gene therapy. 

Another great #ASGCT conference is in the books!     Thank you to the American Society of Gene & Cell Therapy conference organizers and all those who attended our late-breaking oral presentation on #gaucher disease, and poster presentation from our #Parkinsons disease research program.     We enjoyed connecting with industry peers and look forward to what lies ahead for our #genetherapy program!     #ASGCT2024 #biotech 

Today Freeline will share positive new data from its Phase 1/2 study of its novel AAV #genetherapy candidate for #gaucher disease in a late-breaking oral presentation at the American Society of Gene & Cell Therapy's 27th annual meeting.     The company will also share highlights from its #Parkinsons disease research program, which builds on Freeline’s work in Gaucher disease.    Learn more about the presentations here: https://lnkd.in/g7Aneekp   #ASGCT2024 #raredisease #biotech